Indications and recommendations for the use of recombinant human growth hormone in adult short bowel syndrome patients dependent on parenteral nutrition.
Given the lack of published guidelines regarding the use of trophic factors to treat patients with short bowel syndrome (SBS), a group of experts in the field convened to discuss best-practice strategies. Trophic factors, such as recombinant human growth hormone (r-hGH) and glucagon-like peptide-2 (GLP-2), may enhance intestinal adaptation and decrease parenteral nutrition (PN) requirements; therefore, their utility in treating SBS patients was evaluated. Available clinical data on use of r-hGH therapy in SBS patients were discussed, as were the utility of r-hGH in the PN weaning process, the optimal timing of r-hGH therapy, and how to select appropriate patients for r-hGH therapy. In addition, contraindications and precautions as well as adverse effects of r-hGH treatment were discussed. The meeting culminated with the development of a treatment algorithm to summarize best-practice recommendations for the management of SBS in adult patients. This algorithm involves attempting to wean patients off PN without the use of trophic factors. If this is unsuccessful, it is recommended that patients be treated with an r-hGH regimen or participate in investigational studies using other trophic factors.
Steiger
Ezra
E
Intestinal Rehabilitation Program, Nutrition Support and Vascular Access Department, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. STEIGEE@ccf.org
DiBaise
John K
JK
Messing
Bernard
B
Matarese
Laura E
LE
Blethen
Sandra
S
D000328:Adult; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D010288:Parenteral Nutrition; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012778:Short Bowel Syndrome / Q000628:therapy*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D019382:Human Growth Hormone